NCT07546877Recruiting
High-Frequency Repetitive Transcranial Magnetic Stimulation for Cognitive Improvement in Patients With Post-Stroke Cognitive Impairment
Efficacy of High-Frequency Repetitive Transcranial Magnetic Stimulation in Patients With Post-Stroke Cognitive Impairment: A Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 23 Apr 2026
Brief summary (registry, in English)
To clarify the clinical efficacy of high-frequency rTMS on patients with post-stroke cognitive impairment, fNIRS and EEG techniques were used to observe the changes in brain functional activities of patients with post-stroke cognitive impairment after rTMS treatment, and to clarify the neuroregulatory effect of rTMS on patients with post-stroke cognitive impairment.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 14 Apr 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Jul 2027
- Lead sponsor
- Qilu Hospital of Shandong University
- Diseases
- Stroke
- NCT number
- NCT07546877
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 1 Apr 2026 to the primary completion date, 1 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Has a history of brain tumors, brain trauma, epilepsy or mental disorders;
- Had cognitive impairment before the stroke;
- Had implanted metal or electronic devices (such as cardiac pacemakers, cochlear implants, deep brain stimulators, aneurysm clips, internal fixation devices after ventriculoperitoneal shunt surgery, etc.);
- Has other serious diseases that may affect the study;
Other
- Underwent craniotomy or had a skull defect;
- Pregnant women
Who the study is looking for
- Meets the diagnostic criteria for stroke as stipulated in the "Guidelines for the Prevention and Treatment of Stroke in China (2021 Edition)", and the initial stroke diagnosis is confirmed by cranial CT or MRI examination, and is confirmed as the initial onset;
- The disease course is 1-12 months;
- Has cognitive impairment (MoCA \< 26 points, education years ≤ 12 years, add 1 point to the score result);
- Age 35-75 years old, gender not limited;
- Stable vital signs, no progressive neurological symptoms;
- No severe aphasia, visual or auditory impairment, and able to complete the research protocol;
- Not using antidepressant drugs simultaneously;
- If using cognitive-improving drugs (such as donepezil, memantine), it should last for at least 3 weeks or more, and no dose adjustment will be made during the enrollment period;
- Voluntarily participate and sign the informed consent form.
Age in the registry: 35 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Qilu Hospital of Shandong University Coordinator of this site? Confirm its status | Jinan | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.